Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance
US FDA meeting directs attention to the vitiligo patient experience as a small group of potential treatments, led by topical Janus kinase inhibitors, are at the Phase II hinge point.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
A dozen applications for new drugs and significant new indications are on the US FDA’s calendar of goal dates, including breakthrough-designated applications from Bristol-Myers Squibb and Boehringer Ingelheim.